HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share. The repurchase program was announced by the company on March 15, 2016, and was completed on August 18, 2016.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.